HYPERTENSION

Articles Contributed By:
John Davis Cantwell, M.D., MACP, FACC
William H. Cleveland, M.D.
Rachel Harris, M.D., MPH
Jason Higdon, M.D.
Angus C. Howard, M.D.
Janice P. Lea, M.D., MSc, FASN
Brittany Thomas, M.D.
Jennifer Zrelof, M.D

Spotlight: Residency

Special Feature: STAT!
Feel like improving care for the community should improve your bottom line?

The feeling is mutual.

As the best evaluators, analyzers and managers of liability risk, MagMutual understands how to help hospitals and physicians identify opportunities to improve performance and reduce costs. In addition, our PolicyOwners℠ receive exceptional benefits through support programs and Patient Safety resources – just a few of the reasons we have grown to become the largest healthcare liability insurer in the Southeast, and leading mutual insurer in many states.

Experience the MagMutual PolicyOwner℠ difference, call 800-282-4882 or visit MagMutual.com
CONTENTS
Vol. 87, No. 3, 2016

Contributors

HYPERTENSION

5 Hypertension
By William H. Cleveland, M.D.

6 12 Tips for Hypertension in the Athlete
By John Davis Cantwell, M.D., MACP, FACC

8 Adolescent Hypertension: Assessment of Future Cardiac Risk
By Rachel Harris, M.D., MPH

12 White Coat Hypertension: Myths vs. Facts
By Angus C. Howard, M.D.

18 Hypertension & Sexual Dysfunction: Let’s Start the Conversation
By Brittany Thomas, M.D.

20 A Hypertension 2016 Update
Should We SPRINT to a Lower Blood Pressure Goal?
By Janice P. Lea, M.D., MSc, FASN

24 Teaming Up to Treat Hypertension
Using Team-based Care and Population Health to Improve Blood Pressure Control
By Jennifer Zreloff, M.D., and Jason Higdon, M.D.

SPECIAL FEATURE

28 STAT!
Specialty Clinic Brings Immediacy to Lung Cancer Care
By Helen K. Kelley

SPOTLIGHT

30 Residency: Atlanta Hospitals and Universities Work to Keep Residents in Georgia
By Helen K. Kelley

MEDICAL ASSOCIATION OF ATLANTA | 1
National Leader in Organ Transplantation

Serving your patients, right here in Georgia.

Emory Transplant Center ranks 7th among transplant programs across the nation based on adult transplant volumes. Annually, we perform more than 440 adult transplants. Our experience, coupled with continued excellent outcomes in all solid organ programs, makes us a leading transplant destination in the nation, serving patients in Georgia and the Southeast.
CONTRIBUTING WRITERS

GUEST EDITOR

William H. Cleveland, MD, Dr. Cleveland is a nephrologist serving on the medical staff of seven Atlanta hospitals, and he is also medical director for two dialysis centers. He is President of Southwest Atlanta Nephrology, PC and is a past president of the then Crawford Long Hospital Medical Staff. He currently serves on the Emory University Healthcare Board and previously served on various medical school boards, including the Board of Regents of the University System of Georgia.

John Davis Cantwell, MD, Dr. Cantwell, a third generation physician from Wisconsin, is a cardiologist with the Piedmont Heart Institute in Atlanta. After majoring in English at Duke University, Dr. Cantwell went on to pursue medicine at Northwestern Medical School. He then interned at the University of Florida, did his residency at the Mayo Clinic, and completed cardiology fellowships at the University of California, San Diego and Emory University. He served as Chief Medical Officer for the 1996 Olympic Games.

Rachel Harris, MD, MPH, Dr. Harris serves as Assistant Professor at Morehouse School of Medicine, Adjunct Assistant Professor at Emory University and Staff Cardiologist at the Atlanta VA including the Ft. McPherson Women’s Center of Excellence. Dr. Harris passionately enjoys teaching and also serves as a Morehouse School of Medicine Internal Medicine Residency Associate Program Director. Her research interests include dietary approaches to reduction in CVD risk, Women and CVD, Obesity and Preventive Cardiology. Dr. Harris is Board Certified in Cardiovascular Diseases, Internal Medicine, Nuclear Cardiology and Echocardiography. She serves as the Echocardiography Lab Co-Director at Grady Hospital in Atlanta, GA.

Angus C. Howard, MD, MBA, Dr. Howard graduated from Mercer University and received his Medical Degree from the Medical College of Georgia. After successfully completing boards in Internal Medicine and Nephrology, Dr. Howard received his MBA at Kennesaw State University in 1999. Dr. Howard has been practicing in Atlanta since 1991 and is Vice President of Southwest Atlanta Nephrology, PC since 1995. He lives in Decatur with his wife and three daughters.

Janice P. Lea, MD, MSc, FASN, Dr. Lea is a Professor of Medicine at Emory University and is board-certified in Nephrology and Hypertension. She received her medical degree from The University of Texas Medical Branch at Galveston and completed her residency in Internal Medicine and Nephrology fellowship at Emory University. She has been in clinical practice at Emory for 20 years. Dr. Lea is the Chief Medical Director of Emory Dialysis and has been named one of Atlanta’s Top Doctors for the past eight years. She is a nationally-renowned expert in Hypertension and is designated a “Clinical Specialist in Hypertension” by the American Society of Hypertension.

Brittany Thomas, MD, Dr. Thomas, a native of Atlanta, Georgia, received her medical degree from Morehouse School of Medicine graduating Magnum Cum Laude. She is an inductee of Alpha Omega Alpha Honor Medical Society. Dr. Thomas completed her Internal Medicine Residency and Nephrology Fellowship at Emory University School of Medicine. She enjoys participating in community health fairs with the goals of increasing awareness of kidney disease and eliminating health disparities. She is an active member of multiple medical societies.

Jennifer Zreloff, MD, Dr. Zreloff is a practicing General Internist and Assistant Professor at The Emory Clinic. She graduated medical school from University of Alabama School of Medicine and completed her residency at Oregon Health Sciences University. She currently also serves as medical director of Emory Patient-Centered Primary Care (Emory Clinic’s first NCQA recognized medical home) and medical director of Emory University Hospital Local Healthcare Network.
Shines The Light on Hypertension

Excellence In Healthcare Begins Here

Dr. Angus C. Howard, Jr.
Dr. Evelyn C. Lewis
Dr. Tanjela M. Jackson
Dr. William H. Cleveland
Dr. Michael D. Brathwaite
Dr. Sammy M. Mugambi
Dr. Brittanay J. Thomas

ATLANTA
3620 M.L.K. Jr. Dr.
404-696-7300

MIDTOWN
121 Linden Ave.
404-815-7217

LITHONIA
2485 Park Central Blvd.
404-564-4991

EAST POINT
2669 Church Street
404-209-0113

DECATUR
1987 Candler Road
404-534-0183
Hypertension has a long history involving an evolution in medical knowledge and clinical technology. Ancient Egyptians and Greeks observed the pulse frequency, size, strength and rhythm. They believed the heart speaks out of every limb. (Herophilus 335-280 BC)\(^1\). To give a historical perspective, in the early 1800s clinical measurement of blood pressure was achieved with a cumbersome device as illustrated on the cover of this edition.

In 1905, a Russian surgeon named Dr. Nikolai Korotkoff\(^2\) reported that when he placed a stethoscope over the brachial artery, a tapping sound could be heard as an inflated cuff was deflated. This provided a practical way for systolic and diastolic blood pressures to be measured.

As measuring and recording blood pressure became more common, elevated blood pressure (hypertension) was recognized by the 1940s. Debate at the time centered on whether hypertension was harmful or helpful, and the term benign hypertension was established.

By the late 1950s, clinical trials documented that lowering blood pressure with thiazide medication was effective. Debate continued until the 1960s, when the U.S. Veterans Study\(^3\) convincingly showed that lowering high blood pressure is associated with a reduction in strokes. Since that time, “observational studies have firmly established the relationship between blood pressure and cardiovascular disease to be direct and progressive.”\(^4\)

Today, clinical hypertension has expanded into a wide spectrum of medical classifications, including malignant, accelerated, secondary, pregnancy associated, adult, adolescent, pediatric, systolic, diastolic, nocturnal and white-coat hypertension, to name only a few.

The medical evaluation of hypertension now requires the understanding of the above classifications along with the appropriate diagnostic and therapeutic options for each classification. Our medical literature has provided specific blood pressure targets, and the pharmacological industry has provided more than 200 oral medications from which physicians can choose. With these advances, the healthcare team can tailor their patients’ treatment regimen to achieve maximum blood pressure benefit with minimal to no side effects.

As the medical landscape in the 21st century changes from individual physician-patient interactions to patient-clinical team interactions, innovative approaches are being used, including new wireless technologies to improve clinical effectiveness, quality and patient satisfaction.

We are pleased to have six outstanding original articles that address important current topics in hypertension. Our physician authors are highly experienced in treating patients with hypertension, and their articles provide important information to our physician community.

Dr. John Davis Cantwell gives us 12 tips to maintaining optimal blood pressure in young athletes.

Dr. Rachel Harris shows us how obesity plays into hypertension among our adolescent population, of which approximately 20 percent are affected, and asks some compelling questions that could cause us to consider redefining and treating hypertension.

Dr. Angus Howard steers us away from the myths and towards the facts of white-coat hypertension.

Dr. Brittany Thomas wants to start the conversation about hypertension and sexual dysfunction, and she does not want to leave the women out of this conversation.

Dr. Janice Lea’s article, “Should we SPRINT to a Lower Blood Pressure Goal,” hones in on the current recommendations and blood pressure goals.

Dr. Jennifer Zreloff along with co-author Dr Jason Higdon wisely advises us to “shift our practice style away from episodic care to comprehensive, longitudinal care that can help more of our patients reach their health goals.”

References
12 TIPS FOR HYPERTENSION IN THE ATHLETE

By John Davis Cantwell, M.D., MACP, FACC

For the past 40 years, I have been doing pre-season Atlanta Braves baseball physicals at their spring training facility in Florida (Fig 1). Thirty-five years ago, I began doing pre-season cardiovascular examinations on freshman Georgia Tech athletes.

Usually every year there are several athletes noted to have hypertension. This is not surprising, since prior surveys suggest that 3.5 percent of children and up to 9 percent of young adults are hypertensive1. Yet, in all those years, we have never had to disqualify an athlete from competition due to this disorder.

I have a mental checklist in evaluating the hypertensive athlete, which includes:

1. Using a wide cuff in large athletes. I also check the blood pressure in both arms at least once.

2. Arranging to get multiple follow-up blood pressure (BP) readings with the athletic trainer or with the athlete (using an Omron home arm BP cuff), noting the findings on our graph paper chart.

3. Taking a thorough family history, especially regarding hypertension, strokes and early coronary events (male relatives < age 55, female relatives < age 65).

4. Asking about weekly caffeine and alcohol intake and use of nonsteroidal drugs, amphetamines and anabolic steroids.

5. Checking the body mass index. The BodPod is a more accurate determination of excess body fat in heavily muscled, weight-training athletes.

6. Discussing the athletes’ typical daily diet, including their sodium intake.

7. Reviewing the urinalysis, blood creatinine, calcium, TSH and lipid results.

8. Looking at the QRS voltage on the ECG. We find it to be falsely suggestive of myocardial hypertrophy, especially in some of the Georgia Tech track athletes, compared to the more precise echocardiographic readings.

9. Remember the ABCDs in choosing drug therapy, when indicated: Ace/ARB, Beta blocker—best in young, whites. Calcium channel blockers, Diuretics—in older, blacks. However, I usually do not start with beta blockers in any athlete as it seems to affect the perceived exertion level in some, while athletes have enough issues with sweating and fluid balance without adding a diuretic. Accordingly, I usually start with a low-cost generic ACE or ARB (like lisinopril, losartan), watching the creatinine and potassium levels. Be sure that any drug you prescribe is okay with the appropriate governing body, like the NCAA or International Olympic Committee (IOC).

10. Consider a 24-hour continuous blood pressure monitor reading in selected cases. Unfortunately, this is not readily available.

Fig. 1. The author with Hall-of-Fame pitcher John Smoltz.
11 I rarely screen for pheochromocytomas, Conn’s syndrome, and renal artery abnormalities, but I do listen for abdominal bruits, check for radial and femoral pulse delays and auscultate the posterior chest to exclude coarctation, but have never found these disorders.

12 Be aware of the new American College of Cardiology Guidelines on dealing with a hypertensive athlete.² Finally, bear in mind as Harvard cardiologist, Elliott Antman, M.D., recently stated: “The epidemiologic evidence clearly shows that increased blood pressure relates to an increased risk for cardiovascular events across a blood pressure range from 115/75 mmHg to 185/115 mmHg.”³ As Ventura and Lavie remind us, “Projecting into the athlete’s future, for every 20 mmHg systolic BP reading above 115 mmHg and/or 10 mmHg diastolic reading above 75 mmHg, there is a two-fold increase in mortality associated with strokes and coronary artery disease.”⁴

REFERENCES:

Acknowledgments: Karen Galloway prepared the manuscript and Stacie Waddell the figure.
Hypertension affects one in four adults in the U.S. and remains the leading modifiable cause of chronic illness in the world. While the correlation between hypertension and cardiovascular risk has been established in adults, less data exists for adolescents. What has been shown is that adult blood pressure correlates with childhood blood pressure, body size and obesity from childhood to adult life, with those who are most obese as adults having shown the greatest increase in weight for height from their childhood years.

Since the 1990s, hypertension and prehypertension have been increasing among children and adolescents. From 2003 to 2006, among children and adolescents aged 8 to 17 years, the prevalence of prehypertension was approximately 14 percent in males and approximately 6 percent in females, and the prevalence of hypertension was estimated to be 3 percent-4 percent in various studies.

From 1997 to 2006, hospitalization rates for children and adolescents with a diagnosis of hypertension doubled, from approximately 18 cases per 100,000 pediatric hospital discharges in 1997 to approximately 35 cases per 100,000 in 2006. The prevalence of hypertension among all adolescents remains approximately 3.5 percent, with rates of prehypertension even as high as 15 percent.

Traditionally, conventional wisdom taught that while essential hypertension was highly prevalent in adults, children and adolescents with hypertension usually had a secondary cause for elevated blood pressure. While it’s still true that hypertensive children are more likely than adults to have a secondary cause, obesity-related essential hypertension is becoming the predominant form of blood pressure abnormality seen in adolescents.

Obesity affects approximately 20 percent of adolescents in the United States, and the prevalence of hypertension is much higher among obese adolescents compared with non-obese adolescents. The correlation between body mass index and blood pressure in adolescence is moderate to strong in most studies and strongest in those classified as overweight or obese.

In this population, the evaluation of hypertension should begin with a confirmation of the blood pressure elevation followed by a focused diagnostic work-up to detect possible secondary causes of hypertension. Primary or essential hypertension is diagnosed when persistently elevated (three or more separate occasions) blood pressure cannot be explained by any underlying organic cause.

According to the recommendations of the Task Force on Blood Pressure Control in Children, children and adolescents age 1 to 17 are considered hypertensive if their average systolic and/or diastolic blood pressure readings are at or above the 95th percentile (based on age, sex, and height) on at least three separate occasions (Table 1).

Close monitoring should be performed for those with prehypertension as well, given that an analysis of the National Childhood Blood Pressure database found that 14 percent of adolescents with prehypertension developed elevated blood pressure within two years.

Left ventricular hypertrophy (LVH) is a powerful independent risk factor for cardiovascular morbidity and
mortality among hypertensive patients. Among children and adolescents with hypertension, as many as one in three has target organ damage, especially left ventricular hypertrophy.\(^3\)

Adolescents with significantly elevated blood pressure require a comprehensive assessment of end-organ damage and cardiovascular risk. This assessment should include an echocardiogram and renal ultrasound in all children with persistently elevated blood pressure. Moreover, as an ECG is a less reliable indicator of ventricular mass in children, echocardiography is the most sensitive and specific tool to assess left ventricular hypertrophy in childhood.\(^6\)

Additionally, because LVH is such a strong marker of end-organ damage in children and an early predictor of heart disease in adults, the presence of LVH is an indication to initiate or intensify pharmacologic treatment of hypertension.\(^6\)

Assadi demonstrated that in children with essential hypertension, the treatment of microalbuminuria by renoprotective therapy (angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers) was associated with LVH regression.\(^5\) It is also clinically important to recognize that while LVH is a modifiable risk factor, its management is more complex than just blood pressure control. As left ventricular hypertrophy strongly predicts cardiovascular morbidity and overall mortality in hypertensive patients,\(^9,13\) antihypertensive treatment that causes LVH regression decreases rates of adverse cardiovascular events and improves survival, independent of how much the blood pressure is lowered.\(^9,13\)

A number of nonmodifiable and modifiable factors have been implicated in the development of hypertension. Importantly, certain clinical and biochemical markers in overweight adolescents are indicative of high risk for hypertension, including family history of hypertension and hyperinsulinemia.\(^7\)

Despite the absence of robust longitudinal data to assess outcome risk among adolescents with hypertension, data on surrogate markers of vascular injury indicate that vascular abnormality does occur. Structural changes in forearm vessels of obese adolescents with hypertension were detected by Rocchini et al.,\(^5\) who observed a significant correlation between peripheral vascular resistance at maximum vasodilation and measures of insulin resistance. The Pathologic Determinants of Atherosclerosis in Youth study demonstrated quantifiable vessel injury is detectable in adolescents and young adults, and there is a relationship, even in youth, between early atherosclerotic lesions and cardiovascular risk factors, including hypertension, dyslipidemia and smoking exposure.\(^5\)

Carotid artery intimal medial thickness (cIMT) has also been found to be greater in young adults who have had multiple risk factors since childhood.\(^5\)
Since the 1990s, hypertension and prehypertension have been increasing among children and adolescents.

While examining modifiable risk factors, a focus on behavior is paramount. One must ask the question: Are population- and individual-level approaches that support the establishment of positive health behaviors early in life the foundation of preserving ideal cardiovascular health and promoting positive cardiovascular outcomes?

While the majority of adolescents are free of cardiovascular disease, far fewer are free of cardiovascular disease risk factors, especially lifestyle factors such as poor exercise and dietary habits. Evidence of the effectiveness of long-term dietary intervention for the reduction of risk factors for cardiovascular disease (CVD) in children is limited, but ample data suggest that changes in specific dietary macronutrients (eg, dietary fat and carbohydrates) and micronutrients (eg, sodium and calcium) have an impact on the risk of CVD.

Yang et al analyzed NHANES database to assess the association between usual dietary sodium intake and blood pressure among U.S. children and adolescents ages 8-18 years old, overall and by weight status, and found sodium intake and weight status to have synergistic effects on risk for pre-hypertension and hypertension with a stronger association among those who are overweight or obese. Moreover, combined diet and physical activity interventions have led to a significantly greater reduction in both systolic blood pressure and diastolic blood pressure than the diet-only or physical activity-only intervention.

While continued longitudinal studies are needed to assess long-term risk, there are many pressing potential areas of focus, such as a re-evaluation of the definition of prehypertension and hypertension. It is currently based on the upper segment of the normal blood pressure distribution. Can the percentiles currently used underestimate the longitudinal risk? Is the true threshold lower? Can additional predictors such as BP to height ratio be as accurate and not as cumbersome as current practice? Is there an increased role for 24-h ambulatory blood pressure monitoring (ABPM) as an initial confirmatory test in all adolescents with suspected hypertension due to elevated office readings?

Cumulative BP measurements on an individual child provides a better definition of the BP phenotype, with ambulatory BP monitoring (ABPM) becoming a potential useful tool for evaluating BP patterns (with some normative ABPM data now available).

Accumulating evidence continues to support elevated blood pressure levels in adolescence as a precursor of elevated blood pressure in adulthood, making it of utmost importance to identify elevated blood pressure in childhood and adolescence. Primary therapy for obesity-related hypertension in adolescents begins with weight loss and targeted dietary intervention. It may also include antihypertensive medications if target-organ damage or other indications for drug therapy are present. The emphasis for reduction of future adult cardiovascular risk continues by addressing all modifiable factors with early recognition and intervention.

For more information, please visit www.nhlbi.nih.gov/files/docs/resources/heart/hbp_ped.pdf

References
LONGEVITY AND STABILITY
MEDICAL PROFESSIONAL LIABILITY INSURANCE

NORCAL Mutual now offers new, enhanced coverage in Georgia — previously offered by its subsidiary, Medicus Insurance Company. NORCAL Mutual brings an A.M. Best “A” (Excellent) rating and 40 years of strength and stability to Georgia physicians who deserve a committed MPLI provider.

Talk to an agent/broker about NORCAL Mutual today.
NORCALMUTUAL.COM | 844.4NORCAL

Medicus is a subsidiary of NORCAL Mutual. Coverage in Georgia will be offered by NORCAL Mutual Insurance Company.
The diagnosis of white coat hypertension (also called “isolated clinic,” “office hypertension” or “white-coat effect”) is applied to patients with office readings that average more than 140/90 mmHg and reliable out-of-office readings that average less than 140/90 mmHg.25

Observational and sequential studies have clearly demonstrated that in patients who have been diagnosed with hypertension, on the first office visit to a “new” clinician there is a mean 15 and 7 mm Hg fall in the systolic and diastolic blood pressure, respectively, by the third visit26, and some patients do not reach a stable value until the sixth visit.27

Most definitions of the “white coat effect” or “white coat hypertension” use the values obtained with Ambulatory Blood Pressure Monitor (ABPM) to calculate the difference in Blood Pressure (BP) between the healthcare settings versus non-healthcare setting.

Blood pressure typically decreases at night for both normotensive and hypertensive individuals. Therefore, the daytime BP (ABPM) is often used to calculate the delta in BP changes in clinic versus non-clinic.6

The average nocturnal blood pressure is approximately 15 percent lower than daytime values. The failure of the BP to fall by at least 10 percent during sleep is called “nondipping,” or an increase in BP at night (“reverse dipping”) correlates with increased risk of ESRD and fatal and nonfatal cardiovascular events among patients with chronic renal disease by 60 percent to 70 percent.2, 6

Ambulatory blood pressure monitoring (ABPM) is obtained by using a device worn by the patient that takes blood pressures measurements usually over a 24-hour period, typically ranging from 70 to 80 readings in 24 hours (usually every 15 to 20 minutes during the daytime and every 30 to 60 minutes during sleep). These blood pressures are recorded on the device, and the average (or mean) day (diurnal) or night (nocturnal) blood pressures are
determined from the data by a computer. The percentage of blood pressure readings exceeding the upper limit of normal can also be calculated.\textsuperscript{1,6}

The definition of hypertension using ABPM interpretation is the 24-hour average blood pressure greater than or equal to 135/85 mmHg; daytime (awake) blood pressure greater than or equal to 140/90 mmHg; or nighttime (asleep) blood pressure greater than or equal to 125/75 mmHg.\textsuperscript{1,25}

Typical indications and clinical usages for ABPM in accordance with published practice guidelines and expert panel recommendations include:\textsuperscript{25}

- Suspected white coat hypertension
- Suspected episodic hypertension (e.g., pheochromocytoma)
- Patients with evidence of end-organ damage (LVH) despite repeatedly normal blood pressure when measured in the clinic (Masked Hypertension)
- Hypertension resistant to increasing medications
- Hypotensive symptoms while taking antihypertensive medications
- Autonomic dysfunction

\textbf{Clinical Vignette}

The prevalence of white coat hypertension ranges from 10 to 20 percent and appears to be higher in children and the elderly.\textsuperscript{15, 21-23} It is also present in patients with apparent “resistant” hypertension.

Ms. O.D. is a 70-year-old retired female educator who was referred to Southwest Atlanta Nephrology for evaluation of azotemia based on labs collected (06/16/2015), which demonstrated BUN/CR 25/1.38 mg/dl with corresponding estimated Glomerular Filtration Rate (eGFR) 45 ml/min.

She was seen on initial consultation Sept. 21, 2015, and documented with office BP reading of 118/60 (right arm). On the second office visit (October 26), Ms. O.D. was switched from Losartan-HCT (100-25 mg) to plain Losartan (100 mg) due to complaints of morning orthostasis (office BP reading was 108/70 mmHg in the rt. arm and weight was 199 lbs.).

On the third office visit (November 23), Ms. O.D.’s office blood pressure was 134/70 (right arm) with a corresponding weight of 203 lbs., and she failed to bring records of self-recorded Home Blood Pressure readings as instructed during the previous office visit. At the fourth
office visit (December 23), the office blood pressure was 104/60 mmHg (right arm) with a weight of 199 lbs. Ms. O.D. did not bring her Home Blood Pressure logs back on the return office visit as instructed.

Results of labs collected Dec. 23, 2015, was remarkable for resolution of azotemia with BUN/Cr 18/0.89 and corresponding eGFR 76 ml/min. The plans for the return visit in three months include making arrangements for patient to undergo a 24–hour ABPM to further evaluate patient's hypertension management and risk stratification for hypertensive cardiovascular events (unpublished personal data).

**Prognosis**

The cardiovascular risk associated with white coat hypertension, while greater than normotensive individuals, is well below those associated with sustained or masked hypertension and varies from being statistically significant to nonstatistically significant in various meta-analyses.\(^{15,20,23,25}\)

However, it is generally widely accepted that patients with white coat hypertension are also at high risk for developing sustained hypertension. In a study of 81 patients with office hypertension (mean blood pressure 154/970) and normal 12-hour ambulatory blood pressure (mean blood pressure 125/77 mmHg), 60 (74 percent) had a mean ambulatory blood pressure above 140/90 mmHg after five to six years of follow-up.\(^{29}\)

Therefore, the difference in cardiovascular (CV) risk associated with white coat hypertension cited in different meta-analyses may be related to the development of increased CV risks when they cross into the hypertensive category, as approximately 40 percent of participants have been reported to do after several years of follow-up.\(^{5}\)

**Recommendations**

Although there are no universally accepted guidelines or recommendations for the treatment of White Coat Hypertension, we should include its management in the process of risk stratification to minimize hypertensive cardiovascular events.

While the risk of cardiovascular events is not as great or well established as in “sustained hypertension” and “masked hypertension,” the risk associated with white coat hypertension is greater than in normotensive individuals.\(^{3}\)
MORE INSIGHT

helps you make the most of your practice’s revenue cycle.

KNOW YOU HAVE A DEDICATED BANKER WHO UNDERSTANDS YOUR INDUSTRY AND YOUR NEEDS.

As a healthcare professional, you want to spend more time helping patients and less time worrying about your finances. With dedicated Healthcare Business Bankers, PNC provides tools and guidance to help you get more from your practice.

The PNC Advantage for Healthcare Professionals helps physicians handle a range of cash flow challenges including insurance payments, equipment purchases, and managing receivables and payables. In such a fast-moving business, PNC understands how important it is to have a trusted advisor with deep industry knowledge, dedication and a lasting commitment.

Call a Healthcare Business Banker at 877-566-1355 or go to pnc.com/hcprofessionals

Cash Flow Optimized is a service mark of The PNC Financial Services Group, Inc. (“PNC”). Banking and lending products and services, bank deposit products, and treasury management services, including, but not limited to, services for healthcare providers and payers, are provided by PNC Bank, National Association, a wholly owned subsidiary of PNC and Member FDIC. Lending and leasing products and services, including card services and merchant services, as well as certain other banking products and services, may require credit approval. All loans and lines of credit are subject to credit approval and require automatic payment deduction from a PNC Bank business checking account. Origination and annual fees may apply. ©2015 The PNC Financial Services Group, Inc. All rights reserved, PNC Bank, National Association, Member FDIC.
Furthermore, in certain cases our treatment has more deleterious effects than the process that we are treating. If therapy is withheld, careful monitoring is still indicated for the possible development of sustained hypertension or of end-organ damage, while the patient should be encouraged to engage in lifestyle modifications for lowering blood pressure and healthy living as prescribed in JNC 7 Hypertension Guidelines.25

The risk of hypertensive cardiovascular complications has been shown to correlate more closely with 24-hour, daytime or nighttime ambulatory blood pressure monitoring (ABPM) than with the office blood pressure measurements.8, 9, 10-13

Self-recorded casual blood pressure measurements taken at home and at work correlate more closely with the results of 24-hour ABPM or daytime ambulatory monitoring than BPs taken in the clinician’s office. Therefore, home blood pressure measurements (self-recorded) are an acceptable alternative if ABPM is not available or if cost is a concern — and may also improve hypertension control.7, 25

References
25. Kaplan, NM, Townsend, RR, et al. 2016; Up To Date
Introducing the new Cancer Center at WellStar Kennestone Hospital. Redesigned inside and out to ensure our vision of world-class cancer care is experienced by both patients and families. By changing patient flow, adding new services and enhancing the overall care experienced, a new focus on Mind/Body/Spirit has arrived. With recognition by Becker’s Hospital Review’s “100 Hospitals and Health Systems with Great Oncology Programs,” our redeveloped cancer program offers:

- **Cyberknife® and Tomotherapy®**: the only health system in Georgia offering both forms of radiation therapy.
- **Pancreatic Hepatobiliary Program** structured to reduce the time of diagnosis to treatment.
- **Center for Genetics**, the largest in Georgia
- Nationally recognized **STAT clinics** for lung and prostate cancer.
- **Nurse Navigators** for patients and families
- **Clinical psychologist** for emotional needs
- **Integrative treatment** including acupuncture
- **Patient and Family Advisory Board**

For more information, call 1-877-366-6032. wellstar.org
It has been estimated that more than 150 million men worldwide have some degree of erectile dysfunction. The prevalence of erectile dysfunction is approximately two fold higher in hypertensive patients compared to normotensive patients. Due to the private nature of this problem, erectile dysfunction is often overlooked and left to the patient to initiate discussion. The consequences of unrecognized erectile dysfunction included medication non-adherence and decreased quality of life for the patient and the patient’s partner.

Research suggests that erectile dysfunction is a risk predictor of cardiovascular disease. Physicians should therefore inquire about sexual dysfunction, understand the physiology, recognize medications that contribute to sexual dysfunction and risk stratify patients with erectile dysfunction.

**Pathophysiology**

Normally, the cavernosal nerves synthesize and release nitric oxide (NO) onto the smooth muscle cells of both the corpora cavernosa and the penile arterial system. The NO causes relaxation of the smooth muscle within the media of the penile arterial vessels and cavernosal bodies. With aging, the smooth muscle cells are replaced by collagen fibers. These cells are not able to relax and store blood as well as previously.

Vasculogenic ED results from an impairment of smooth muscle relaxation and occlusion of the cavernosal arteries by atherosclerosis or a combination of these. Hypertension plays a role in ED through various mechanisms, including prolonged exposure to elevated systemic blood pressure, endothelial dysfunction and circulation of vasoactive substances such as angiotensin II. These mechanisms lead to structural and functional alterations in the penile arteries.

**Relationship of ED and CV**

ED is a risk predictor of cardiovascular disease. Approximately 40 percent of men who present with ED are shown to have occult cardiovascular disease. It has been shown that ED precedes the onset of symptomatic CAD by a mean of approximately 3 to 5 years. Men with ED appear to carry a 23 percent increased risk of cardiovascular death. Screening for erectile dysfunction may help to identify and improve the management of cardiovascular risk.

**Treatment**

It is important to exclude other causes of erectile dysfunction before vasculogenic sexual dysfunction is
diagnosed. The mainstay of treatment for ED is lifestyle modification. Moderate physical activity can reduce the risk of erectile dysfunction compared to a sedentary lifestyle. Caloric reduction, weight loss, alcohol reduction and smoking cessation may improve sexual function.

In terms of medical therapy, testosterone therapy may be helpful in men with testosterone deficiency. Regarding antihypertensives, thiazide-class diuretics have been shown to cause erectile dysfunction. Indapamide is rarely associated with an adverse effect on male sexual function.4

The incidence of sexual dysfunction linked to centrally acting antihypertensives such as clonidine has been estimated to be 20 percent.4 Most beta blockers have the potential adverse side effect of erectile dysfunction. The first-generation beta blockers such as propranolol are more likely than the second-generation beta blockers, like metoprolol, to cause erectile dysfunction. Nebivolol, a third-generation beta blocker, may even improve erectile dysfunction through nitric oxide production. ACE inhibitors and calcium channel blockers have a neutral effect on erectile function.

Angiotensin receptor blockers also have a positive effect on erectile function. Angiotensin receptor blockers block the vasoconstrictive action of angiotensin II. Angiotensin receptor blockers are considered a first-line treatment in hypertensive patients with erectile dysfunction.

Phosphodiesterase-5 (PDE5) inhibitors are effective medications used to treat erectile dysfunction. They are useful even for patients on multiple drug regimens unless contraindicated. They cannot be used with long- or short-acting nitrovasodilators due to hypotension. They should be used with caution in patients taking alpha blockers.

When conservative management fails, surgical penile prosthesis (inflatable or semi-rigid) should be considered. An implantable prosthesis has a high satisfaction rate but carries the risks of mechanical failure and infection.

Women
Research regarding female sexual dysfunction (FSD) is limited. The underlying pathophysiology of hypertension contributing to female sexual dysfunction is similar to the role of hypertension in erectile dysfunction. Decreased blood flow from vascular remodeling and atherosclerosis causes clitoral and vaginal insufficiency. In addition, fibrosis of the clitoral smooth muscle and vaginal wall leads to impaired sexual stimulation. The ultimate result is vasculogenic FSD.

Sexual dysfunction was found in 42.1 percent of women with essential hypertension compared with 19.4 percent of normotensive women.5 The duration of hypertension, beta blockers and uncontrolled hypertension have been linked to sexual dysfunction in women. Hypertension is associated with decreased lubrication and orgasm and increased pain.6

Although there is limited data on female sexual dysfunction, it is critical to recognize that there is an association with antihypertensive therapy. Changes in medication may improve quality of life and compliance with therapy.

In August 2015, the FDA approved flibanserin for premenopausal women with hypoactive sexual desire disorder. This medication does not target vasculogenic sexual dysfunction but may improve libido in those suffering from the disorder. Flibanserin is a centrally acting serotonin receptor 1A agonist and serotonin receptor 2A antagonist that results in transient decreases in serotonin and increases in dopamine and norepinephrine in certain regions of the brain.7 It has been associated with hypotension and dizziness and should not be taken with alcohol.

Sexual dysfunction is commonly associated with hypertension and antihypertensive medications in both men and women. It is time to start conversations with patients regarding this matter to improve quality of life, medication adherence and risk factor reduction.
Should We SPRINT To A Lower Blood Pressure Goal?

A Hypertension 2016 Update

By Janice P. Lea, M.D., MSc, FASN

Hypertension is a major independent risk factor for coronary artery disease, stroke, heart failure and renal failure. One of every three American adults — or approximately 67 million adults (31 percent) — has hypertension (HTN). Only 54 percent of hypertensive Americans have their blood pressure (BP) controlled below 140/90 mm Hg, with lower control rates in African-Americans and Hispanics.1,2

There has been much debate regarding recent BP guidelines that led to the lateness of the Joint National Committee (JNC)-8 report. We will review differences in the recent JNC-8 report from the 7th report, review the African-American Study of Hypertension and Kidney Disease trial (AASK) and discuss the recently published Systolic Blood Pressure Intervention Trial (SPRINT). Through this review, you will gain awareness of the key differences and controversies among the multitude of new hypertension practice guidelines and clinical trials, be able to select optimal drug regimens to improve hypertension control rates, and become familiar with novel non-pharmacologic therapies for the treatment of hypertension.

JNC-8 Guideline

In 2014, JNC-8 (nicknamed JNC-Late) published the evidence-based guideline for the management of high BP in adults. JNC-7, which was published more than 10 years ago, recommended a BP goal of <140/90 in the general population but emphasized a lower BP goal of < 130/80 in patients with diabetes or chronic kidney disease (CKD). It also made specific BP class recommendations based on compelling indications.

The most recent JNC report is characterized by a systematic review of the literature with an emphasis on randomized, controlled clinical trials.3,4 The committee provided nine graded recommendations based on the strength of the available evidence: grade A – E. The recommendations are summarized in Table 1.

Table 1: JNC-8

| Recommendation 1: Goal BP of < 150/90 for the general population at 60 years of age or older (Grade A). |
| Recommendation 2 and 3: The target BP for subjects younger than 60 years of age is <140/90mmHg. |
| Recommendation 4 and 5: In the population age 18 years or older with chronic kidney disease or diabetes, BP goal < 140/90 (Grade E). |
| Recommendation 6: Initial drug therapy for nonblack patients (including diabetic patients) should include a thiazide-type diuretic, a calcium channel blocker (CCB), an angiotensin-converting enzyme inhibitor (ACEI), or an angiotensin receptor blocker (ARB) (Grade B). |
| Recommendation 7: Initial drug therapy for black patients should include a thiazide-type diuretic or a CCB. This includes patients with diabetes mellitus (Grade B; for diabetic black patients, Grade C). |
| Recommendation 8: For patients 18 years and older with chronic kidney disease, initial or additional therapy should include an ACEI or ARB, regardless of race or diabetic status (Grade B). |
| Recommendation 9: An algorithm to reach target BP: increase the dose of the initial drug or add a second drug from one of the classes in recommendation 6, then add a third drug if needed. It was also recommended that ACE inhibitors should not be combined with angiotensin receptor blockers due to concerns for hyperkalemia. |
One of the major and somewhat controversial differences from JNC-7 is the recommendation to use a thiazide diuretic or long-acting CCB as initial monotherapy in black patients who do not have kidney disease. This is the first major guideline to specify differences in BP meds according to race and with somewhat weak evidence (Grade B and C).

This was based on a subgroup analysis of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), which reported that ACEIs led to worse CV outcomes than thiazides or CCBs in persons of African ancestry. However, emphasis must be placed on the fact that this recommendation does not apply to African-Americans with kidney disease or proteinuria as several trials, including the African-American Study of Kidney Disease and Hypertension (AASK) Trial, showed benefit of ACEI therapy in slowing renal disease progression.

AASK Trial

The AASK Trial was the largest cohort of African-Americans with hypertensive renal disease. This study was published in the early 2000s when ACEI use was considered ineffective in controlling BP in African-Americans. Results from the AASK trial revealed a significant benefit of initial antihypertensive therapy with an ACEI, ramipril, in comparison to a dihydropyridine (CCB), amlodipine or a beta blocker, metoprolol, for reducing the clinical composite outcome: decline in glomerular filtration rate (GFR), development of end-stage renal disease (ESRD) or death.

In addition, the AASK Trial compared the effect of strict BP < 125/75 mmHg vs. usual BP control - 140/90 mmHg. However, there was no difference in the clinical endpoints according to BP goal. In long-term follow-up, there was a slower rate of renal disease progression with the lower BP goal but only in those with >300 mg proteinuria.

Finally, this study reported that the magnitude of proteinuria reduction impacted the rate of progression. Other major and kidney-specific guidelines still recommend the lower BP goal of <130/80 in proteinuric CKD patients.

SPRINT Trial

The potential benefit of lowering the systolic blood pressure (SBP) goal to <120 mmHg (compared with <140...
mmHg) in nondiabetic older adults with risk factors for cardiovascular disease (CVD) or with CKD was evaluated in the recently published Systolic Blood Pressure Intervention Trial in 2015.

When SPRINT was first designed, well-established clinical guidelines, including JNC-7, recommended a SBP of less than 140 for healthy adults and 130 for adults with kidney disease or diabetes. SPRINT enrolled more than 9,000 patients 50 years or older who had a SBP of 130 to 180 mmHg with at least one cardiovascular risk factor. It is important to emphasize that SPRINT excluded patients with diabetes, symptomatic heart failure, a history of stroke and proteinuria (>1 g/day total protein or >600 mg/day albumin).12

Antihypertensive therapy consisted of an ACE I or ARB (but not both), a long-acting dihydropyridine CCB (typically amlodipine) or a thiazide-like diuretic (ie, chlorthalidone rather than hydrochlorothiazide), or a combination of these drugs to achieve the blood pressure target; other antihypertensive medications were added if needed. The trial was halted early for benefit after a median follow-up of 3.26 years; the key findings from SPRINT are shown in Table 2.

Whether or not these trial findings will swing the pendulum towards more aggressive BP lowering for cardiovascular protection remains to be determined. However, clinicians need to be aware that participants in SPRINT had a significant increase in some serious side effects, including bradycardia, hypotension and syncope, and thus they will need to weigh potential benefits vs. risks, especially when treating elderly patients.

### Conclusion

Most guidelines and recommendations, including those made by panel members from JNC-8 and others, support the use of any of these classes as initial therapy in many patients: thiazide diuretics, CCBs, ACEIs or ARBs. Beta blockers are no longer recommended as initial monotherapy in the absence of a specific (compelling) indication for their use, such as ischemic heart disease or heart failure with decreased ejection fraction.

Recent guidelines have also emphasized the need for 24-hour control of BP and encourage use of ambulatory BP monitoring to guide treatment rather than just office BP measurements. At this time, BP goals for persons <60 and for diabetics remain <140/90, but for CKD with proteinuria > 1 gm, most kidney specific guidelines suggest a BP goal of <130/80.

However, findings from SPRINT challenge existing guidelines by reporting that, among older, hypertensive, nondiabetic adults at high risk for cardiovascular disease, targeting a SBP of <120 mmHg can reduce mortality and prevent cardiovascular events, which is in direct contradistinction from JNC-8’s suggestion of a BP goal in the elderly of not less than 150/90. Furthermore, this study excluded persons who might benefit from stricter BP control such as diabetics or persons with a previous stroke.

If a specific secondary cause of hypertension is suspected or if the blood pressure remains elevated despite six months of more intensive treatment, referral to a hypertension specialist is recommended. In the United States, the American Society of Hypertension (ASH) provides a list of hypertension specialists who are members of ASH. This list can be accessed at: www.ash-us.org/htn-specialist/htn-specialists-directory.aspx.

### Table 2: SPRINT

| 1. | Intensive as compared with standard treatment significantly reduced the rate of the primary end point, a composite of myocardial infarction, acute coronary syndrome, stroke, heart failure or cardiovascular death (5.2 percent versus 6.8 percent). |
| 2. | Intensive treatment also significantly reduced mortality (3.3 percent versus 4.5 percent). |
| 3. | Among the 2,646 patients who had CKD at baseline (defined as an eGFR of 15 to 59 mL/min, but < 1 gm proteinuria), intensive treatment did not alter the risk of kidney disease progression. |
In the Atlanta division of CalAtlantic Homes being marketed under the Ryland Homes brand, prices, plans, elevations and specifications are subject to change without notice. Depictions of homes or other features are artist conceptions. Photographs and/or renderings are for illustrative purposes only. Hardscape, landscape, and other items shown may be decorative suggestions that are not included in the purchase price and availability may vary. See Sales Counselor for details on available promotions, restrictions, offer limitations and a complete list of HouseWorks® features. This is not an offer or the solicitation of an offer for the purchase of a new home. This information is not directed to residents of any state that requires registration or permit issuance prior to the publication of such information. © 2016 CalAtlantic Group, Inc. RA2095

Ryland and Standard Pacific, Now One Company, CalAtlantic Homes.

TOWNS AT DRUID HILLS
Homes from the low $500s

Community Features
- Gated community offering 65 luxury townhome homesites
- Shopping, fine dining, entertainment and recreation close by
- Fabulous amenities offering a pool and cabana
- Fantastic location on North Druid Hills Road less than one mile from I-85 and providing excellent commuter access to downtown

For more information, please call Bakari Maxwell or Tarecia Johnson at 404-634-4485.

References
It is estimated that approximately 30 percent of American adults have hypertension. According to data from the National Health and Nutrition Examination Survey (NHANES), the proportion of those patients whose blood pressure is under control has improved but is still only about 50 percent.

With our focus ever moving towards higher-quality care, we need to shift our practice style away from episodic care to comprehensive, longitudinal care that can help more of our patients reach their health goals. Instead of treating only the patients that are on our schedule in the grinding “get them in and get them out” mentality, we can start viewing their care on a continuum.

This is not something providers can successfully achieve and maintain on their own. In order to do this, we need to embrace concepts of team-based care, including population management, evidence-based protocol-driven care and a commitment to process improvement. Team-based care has been shown to improve blood pressure control and lower physician burnout. In this article, we will highlight key principles of team-based care that can be adapted to meet the needs of your practice.

**Population Management**

Being able to identify all of your patients with hypertension is key. Fortunately, this is one of the things that should be made easier because of electronic medical records. Using data extracted from the health record, the ideal report includes meaningful and actionable information at both the patient and practice levels.

Our report shows the current percentage of patients at goal and allows us to follow that percentage over time. We are also able to select those patients who are not at goal and view their last blood pressure reading, date of their last visit and when their next visit is scheduled. Stratifying patients by demographics, co-morbidities and number of medications may help identify subsets of patients who are vulnerable to gaps in care. A good place to start in your EMR are your meaningful use reports, but most vendors also have other population health reporting capabilities. Having access to these types of reports will help lay the foundation for team-based outreach and process improvement.

**Standardization of Care**

An equally important building block in providing team-based care is creating a standard of care in your clinic/system so that all providers agree on evaluation, medications and treatment targets. If there is wide variation, it makes it difficult to empower a team to provide protocol-driven care.

Using evidence-based guidelines to create your standard can help your team know how to do their part. JNC8, ACCORD, and SPRINT are worth reviewing before coming up with the protocol suited for your clinic. Other factors to consider in your protocol are factors that impact compliance (e.g. cost and dosing frequency), surveillance lab tests needed, follow-up intervals and education on lifestyle modifications.

Once you have your standards in place, you can define what roles different team members will play. A useful tool to help document your protocol is millionhearts.hhs.gov/Docs/Hypertension-Protocol.pdf.

**Team Empowerment**

Once you’ve identified your patients with uncontrolled high blood pressure and agreed on treatment standards, you can engage and empower your team to help these patients reach
their goal. Patient education, medication refill protocols and nurse visits for routine follow-up are three ways that your team can make a positive impact.

Patient education is a critical step in patient engagement and can be highly successful with team delivery. Patients may be more candid about their habits with other team members. By teaching your team about lifestyle factors that impact blood pressure and about the consequences of uncontrolled blood pressure, they can take advantage of opportunities to discuss these when working with patients. They may be able communicate these concepts in a way that patients can better understand.

Our EMR has educational handouts that can be added to patients’ discharge paperwork. We’ve reviewed these materials and selected high-yield handouts to be used by the team. Any team member involved in a patient’s in-office care can add appropriate materials to their discharge paperwork.

Medication compliance is key to achieving and maintaining blood pressure control. By employing standing orders for medication refills, your staff help reduce the likelihood that a patient will run out of medication by reducing turnaround time on refill requests.

In our protocol, we require that the original prescription was written with at least a six-month supply and that the patient has been seen and has a basic chemistry on file within the past year. For patients who are due for follow-up, our team contacts the patient to schedule appropriate follow-up while sending in a prescription to bridge the gap until their follow-up.

Finally, your staff can also manage follow-up visits for hypertension. By using a protocol driven by medical assistants (MAs), Kaiser in Northern California increased their rate of patients at goal from 43.6 percent in 2001 to 85.7 percent in 2012. Our licensed practical nurses (LPNs) and registered nurses (RNs) do protocol-driven visits for blood pressure follow-up (Figure 1). The nurse forwards the note to the patient’s provider to review and make additional recommendations as necessary. This has been effective at increasing our rate of patients at goal from 64 percent to 80 percent.

In Georgia, physicians must still write the medications for an individualized patient, but the nurse can play a key role in data acquisition, documentation and patient education. Of note, the most successful test of change we noted was empowering our staff to automatically schedule any patients who were not at goal for a one-month follow up nurse visit.

### Process Improvement

When implementing new processes, it can be helpful to use formal process improvement tools. Setting a specific goal with a deadline (i.e. an aim statement) can help your team get engaged. Once your team agrees on the goal, identifying hurdles to blood pressure control (i.e. using a fishbone) can help identify what steps your clinic can take to help improve control rates for your population.

Beyond patient specific factors, it is important to consider factors from your clinic as well as factors from the system. For example, a

---

**Figure 1**

**Nurse Visit Protocol for Hypertension Follow-up**

1. Review last MD note (or clinical message) to verify patient specific orders for nurse visit

2. Take history from patient
   a. Medication compliance: “Have you missed any doses of your medication in the last 14 days?” If yes, how many doses?
   b. Medication side effects: “Have you experienced any side effects from your medication(s)?” If yes, clarify what side effects.
   c. Self Management Goals: follow-up on progress from most recent goals
      i. If applicable, identify any barriers to achieving those goals

3. Take vitals and document in EMR: Blood pressure, pulse, weight
   a. Make sure to allow the patient to sit for 5 minutes prior to checking blood pressure and that cuff size is appropriate for their arm
   b. If patient complained of dizziness/lightheadedness (after starting a new blood pressure medicine or increasing the dose) then check orthostatic vital signs (blood pressure and pulse first with them lying down and then with them standing up)
      i. Document if they felt lightheaded during this

   **Notify MD immediately if:**
   1. SBP: <90 or >200
   2. DBP: <50 or >120
   3. HR: <40 or >110
   4. Orthostatics are abnormal if:
      a. SBP drops by more than 20 points
      b. DBP drops by more than 10 points
      c. HR increases by more than 20 points

4. Set Self Management goals:
   a. If achieved prior goals, set new ones
   b. If have not achieved prior goals, modify existing goals or change goals depending on barriers identified
      i. Offer nutrition referral if appropriate

5. Document visit in GenMed NSG Note and forward note to MD
Being able to identify all of your patients with hypertension is key. Fortunately, this is one of the things that should be made easier because of electronic medical records.

For hypertension, this can be phone calls to patients to see if they are taking and tolerating their medication. It can also include nurse follow-up visits as discussed above.

The next part of the cycle is population outreach, which is essential to fill in gaps in care. This key step helps identify those who have been missed in the routine episodic care paradigm and bring them back in to your clinic to get them the care they need.

The final part of the longitudinal care cycle is pre-visit planning, when a team member will review the services your patients are due for at their upcoming visit and order them. Examples of services may include urine protein surveillance, electrolytes or an ECG. For more complicated patients, this may include getting notes from any referrals that were made at the prior visit (e.g. nephrology consult). Even if your patient is scheduled for another complaint, having an alert that your patient has hypertension can help facilitate a more comprehensive visit, enabling better control of your hypertensive patients.

Payment models in healthcare are beginning to shift away from solely fee-for-service reimbursement structures. Medicare and many private insurers are moving towards a value-based modifier or quality bonuses based on clinical performance including hypertension control.

Shifting the paradigm from episodic visits where the sole responsibility is on the provider to longitudinal care delivered by a team can help keep you competitive in the shifting medical environment. Applying team-based care delivery strategies can help improve quality of care, decrease burnout rates and keep compensation competitive.

Episodic Care Versus Longitudinal Care

Team-based care changes the paradigm of patient care from episodic care to longitudinal care. Episodic care is defined by care given at discrete times, such as during an appointment, and is therefore dependent on patients coming into the office for care to be received.

Longitudinal care shifts care to a continuum where the office visit is just one of many “touches” your team may be performing to keep your patient population healthy. The paradigm of longitudinal care can be viewed more like a cycle (Figure 2). The cycle can begin with the initial visit, when the provider defines the care plan and goals for the patient. The second part of the cycle is post-visit follow up. The team member responsible for these tasks can vary depending on the staffing of your clinic and can include MAs, LPNs, RNs and nutritionists.

References:
2. Helfrich et al. Elements of Team-Based Care in a Patient-Centered Medical Home are associated with Lower Burnout Among VA primary Care Employees 2014;29(SUPPL 2):S659-66
6. Jaffe et al. The Kaiser Permanente Northern California Hypertension Project 2001-2012: How an integrated care delivery system increased and maintained blood pressure control rates from 44% to 86% in 11 years. Journal of the American Society of Hypertension 2014;8(4S)
Keeping the **game fair**...

...so you’re not **fair game**.

Your Georgia medicine is getting hit from all angles.

You need to stay focused and on point—confident in your coverage.

Get help protecting your practice, with resources that make important decisions easier.

---

Want to reduce risk? [ProAssurance.com/Seminars](#)

800.282.6242 • ProAssurance.com
Lung Cancer Screening Now Available to Local Patients

Dr. William Mayfield encourages Atlanta-area primary care physicians to identify patients at highest risk and refer them only to centers that are accredited to perform lung cancer screening by the American College of Radiology.

"WellStar has a well-established lung screening program that has been providing safe, responsible screening since 2008," he says. "Seventy percent of lung cancers detected through screening are found in the early stages 1 or 2 when it's most survivable. Early-stage lung cancer often has no symptoms. By the time a person starts to show symptoms, the cancer has already advanced to stage 3 or 4. This is why screening is so important."

Screening should be considered for those who are:

A) Ages 55-80 with a 30-pack/year smoking history and either currently smoke or quit less than 15 years ago; or

B) Age 50 and over with a 20-pack/year history of smoking and one of the following risk factors:
   a. Exposure to cancer-causing agents
   b. History of COPD or pulmonary fibrosis
   c. History of cancer
   d. Family history of lung cancer

For more information, contact Vickie Beckler, RN, at 470-793-4032 or 470-793-4AIR (4247)
Two nurse navigators talk with Kathy DeJoseph, a patient with lung cancer who experienced the benefit of a faster treatment as a result of the STAT Clinic.

**High Demand for Efficient Testing and Treatment**

Until recently, WellStar had one STAT Clinic that operated out of Kennestone Hospital on a weekly basis. In early 2016, the health system added a second clinic day each week at Kennestone and opened STAT Clinics at its Cobb and Douglas locations. The Kennestone clinic has grown from seeing 15 to 18 patients per week to a volume of 20 to 25 each week. The Cobb and Douglas clinics are already seeing up to eight patients per week.

Each STAT Clinic has dedicated examination rooms with a waiting area, multiple computers that are tied into WellStar’s medical records and a conference room where physicians, nurses and technicians can gather to review notes and discuss individual cases. Additionally, the clinics are co-located with each hospital’s CT and PET scanners, which can be reserved for STAT Clinic patients. The level of organization, along with access to appropriate resources, has resulted in an ever-growing patient base.

“Many primary care physicians and pulmonologists are sending us all of their patients who exhibit chest abnormalities because our service is so good and the care is so efficient,” Mayfield says. “We’ve grown because of that.”

**Better Patient Outcomes, Improved Bottom Line**

According to Mayfield, the STAT Clinic has ultimately garnered benefits that go beyond patient comfort, including reduced costs.

“In the past, someone with lung, esophageal or chest abnormalities would likely have had repeated CT and PET scans, going from doctor to doctor during their diagnosis period,” he says. “Since all of the necessary physicians see the patient on the same day at the clinic, we’re able to do fewer tests and they don’t have to be repeated.”

Mayfield adds that survival rates for lung cancer patients have improved as a direct result of the faster, more efficient diagnostic and treatment services provided by the clinic.

“The patient experience is better. Patient outcomes are better,” he says. “It’s a magical thing in medicine when you have faster diagnosis and treatment, improved outcomes and lower costs.”

**STAT Stats**

The WellStar Specialty Teams and Treatments (STAT) clinic is:

- Staffed by a team of experts, including a pulmonologist, thoracic surgeon, radiation and medical oncologists, oncology registered dietitian, nurse navigator, medical social worker, counselor and acupuncturist, among others
- An experienced training center for minimally invasive surgery and a member of the Mayo Clinic Care Network
- At the forefront of genetic tumor analysis, offering the latest genetic-based therapies and genomic profiling and tumor analysis
- Ranked in the top five centers nationally for CyberKnife radio surgery volume
- Available to patients in three WellStar locations – Kennestone, Cobb and Douglas

Dr. Mike Andrews, chief cancer officer and Dr. Mayfield review a patient’s case together.

Two nurse navigators talk with Kathy DeJoseph, a patient with lung cancer who experienced the benefit of a faster treatment as a result of the STAT Clinic.
Doctor shortages are critical throughout the country. To address this growing problem in Georgia, educational institutions, health systems, legislators and medical organizations are working to increase the number of residencies offered to medical school graduates.

More Opportunity

“Georgia is in a ‘world of hurt’ for having enough physicians. In fact, some counties have only one or no physicians,” says Waldon Garriss, MD, who serves as the internal medicine director for WellStar Health System’s new residency program. “Georgia has traditionally been a net exporter of physicians. Newly graduated MDs and D.O.s have to leave Georgia to train because there is little opportunity here.

“What makes this situation particularly bad is that about 70 percent of physicians will end up practicing close to their last stop for training,” he adds. “If we’re sending our doctors elsewhere to train, they often don’t come back to Georgia.”

In answer to this need, WellStar has assembled a team of qualified clinicians and resources to achieve accreditation and begin a residency program that has already begun attracting applications from medical graduates. WellStar has completed its first interview season for its internal medicine and obstetrics/gynecology residencies, which will get underway this summer. The health system is currently working on accreditation for two additional residency programs in emergency medicine and surgery.

Garriss emphasizes the importance of reaching out to medical schools in Georgia and surrounding states to make them aware of these new residency opportunities.

“It’s obviously crucial and in keeping with our mission to have doctors who join WellStar and remain in our community, so it’s important for us to reach out to our state medical schools to make sure they know what we’re offering,” he says. “These are the students who already have some roots here in Georgia and the southeast because of school. They have the highest likelihood of staying.”

Patient Base, Specialty Programs Grow

James R. Zaidan, MD, M.B.A., associate dean for graduate medical education (GME) at Emory University School of Medicine, says Emory’s residency programs, a great number of them established many decades ago, have continually expanded over the years in response to a growing patient base.

“There comes a point for most patients when they will need some form of specialized care. As our knowledge of different areas of medicine expands, little segments of those areas break away to become their own specialties, and we are constantly developing training programs for these new specialties,” he says. “When I started as the Associate Dean at Emory 16 years ago, I believe we offered about 67 accredited residency programs. Today, we offer more than 100.”

Zaidan emphasizes Emory’s ever-growing patient base as the driving force behind the growth of its residency program.

“This dramatic growth is directly attributable to the numbers and types of patients who come here. When a new need is identified, our GME faculty members, department chair and program directors will review the possibilities
of creating a new program, asking questions like, ‘Does it make sense?’, ‘Does Georgia need it?’, ‘Do we think this program will do a lot of good?’, and ‘Do we have a faculty member who will want to oversee it?’” he says. “If the answers are ‘yes,’ then we still have to undergo the rigorous accreditation process.”

Some of Emory’s newer residency programs, which will begin this summer, include epilepsy and medical biochemical genetics. Others, such as clinical informatics and interventional radiology, are undergoing the accreditation process.

“Georgia needs more physicians and certainly more primary care physicians. But we must keep in mind that primary care physicians will need experts to whom they can refer patients who require specialized care,” Zaidan says. “We need to have that specialized training here in Georgia.”

Scholarships Benefit Emory and Morehouse Students

In an effort to increase the number of practicing physicians in Georgia, the Medical Association of Atlanta Board of Directors has created four $5,000 scholarships, to be split evenly between senior medical students at Emory University School of Medicine and Morehouse School of Medicine.

To qualify for one of these scholarships, a senior medical student must have matched and committed to a residency program located in Georgia. Preference will be given to those students who have joined the Medical Association of Atlanta and attended MAA events.

State Invests in Rural Practitioners

Gov. Nathan Deal recently announced that Georgia will invest an additional $70 million in two medical schools as a result of a settlement agreement offer from the Centers for Medicare and Medicaid Services. The recipients, Morehouse School of Medicine and Mercer University, were selected based on their continued efforts to place graduates in rural and underserved areas throughout the state.

“The state should receive these funds as a result of a healthcare lawsuit settlement regarding Medicaid reimbursements,” Deal says. “It is only fitting that we in turn invest this money in healthcare education programs, particularly those that prioritize placing primary care physician graduates in high-demand areas throughout the state. We look forward to continue working with these two medical schools to advance their healthcare training and delivery efforts.”

Dr. Valerie Montgomery Rice, president and dean of Morehouse School of Medicine, says the medical school will use the money to help expand classes and its residency programs, as well as recruit new staff. Mercer University President William Underwood says their portion of money will be used to assist students with a commitment to providing primary care in areas of the greatest need.
The Medical Association of Atlanta’s Sponsors

PLATINUM

The Doctors Company is fiercely committed to defending, protecting, and rewarding the practice of good medicine. We are the nation’s largest physician-owned medical malpractice insurer, with 77,000 members, 4.3 billion in assets, and $1.8 billion in surplus.

Learn more at www.thedoctors.com

SILVER

With more than 400 primary- and specialty-care practitioners, The Southeast Permanente Medical Group (TSPMG) is part of Kaiser Permanente’s integrated health care delivery system. Our physicians are connected through one of the largest electronic medical record systems in the U.S., helping us lead the way in improving clinical practice and overall health care quality.

Learn more at physiciancareers kp.org/ga

Join the MAA today!

For membership information, contact David Waldrep, Executive Director at 404-881-1020.

The Medical Association of Atlanta (MAA) is a non-profit association dedicated to the advancement of organized medicine in Atlanta.
GOOD MEDICINE HAS ITS REWARDS—$370 MILLION

WE HAVE RETURNED OVER $370 MILLION TO OUR MEMBERS THROUGH OUR DIVIDEND PROGRAM.

When our insured physicians in the state of Georgia keep patients safe and keep claims low, we all win. The Doctors Company is strong, with 78,000 members and $4.3 billion in assets. This strength allows us to defend, protect, and reward the practice of good medicine like no other.

10% DIVIDEND FOR QUALIFIED GEORGIA MEMBERS

JOIN YOUR COLLEAGUES AT THE DOCTORS COMPANY

800.352.0320
WWW.THEDOCTORS.COM
In Atlanta and throughout Georgia, Northside Hospital provides high quality health care. It begins with our medical and administrative leadership – known for accountability and acknowledged for perennial success. Our employees, volunteers and caregivers are connected, regardless of where they are or what they do. When our patients and families need one, we give them everyone. Because at Northside Hospital, our great doctors have great teams.